Low-Grade Glioma Market Report 2026

Low-Grade Glioma Market Overview

• Low-Grade Glioma market size has reached to $1.47 billion in 2025 • Expected to grow to $1.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Rising Incidence Of Brain Tumours Influences The Market Growth • Market Trend: Advancements In Low-Grade Glioma Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Low-Grade Glioma Market?

Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments. The main drug types of low-grade glioma are trametinib, dabrafenib, ivosidenib, and mirdametinib. Trametinib is a medication used to treat certain types of cancer by inhibiting the MEK1/2 proteins involved in cancer cell growth. Low-grade glioma treatment generally includes a combination of surgery, chemotherapy, and radiation. Medications are delivered through various routes, including oral and topical administration, and are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Low-Grade Glioma Market Growth Forecast?

The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing focus on molecular tumor profiling, rising investment in targeted oncology drugs, growing demand for less aggressive treatment options, expanding access to specialized neuro-oncology care, ongoing clinical trials for novel therapies. Major trends in the forecast period include rising focus on early diagnosis and monitoring, growing adoption of targeted drug therapies, increasing preference for multimodal treatment approaches, expansion of personalized treatment planning, rising long-term disease management strategies.

Global Low-Grade Glioma Market Segmentation

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib 2) By Treatment: Surgery, Chemotherapy, Radiation 3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies Subsegments: 1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors) 2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors) 3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy 4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

What Is The Driver Of The Low-Grade Glioma Market?

The rising incidence of brain tumors is expected to propel the growth of the low-grade glioma market going forward. A brain tumor is an abnormal growth of cells in the brain or surrounding areas, which can be benign or malignant. The rising incidence of brain tumors is due to factors such as increased exposure to radiation, environmental pollutants, genetic predisposition, and aging. Low-grade glioma is helpful for brain tumors by utilizing advanced diagnostic techniques and targeted therapies such as surgery, radiation, and chemotherapy, which help slow tumor progression, preserve neurological function, and improve patient outcomes, making early detection and personalized treatment crucial for managing other brain tumors with similar growth patterns. For instance, in October 2025, according to the Cancer Australia, an Australia-based government agency, in 2023, Australia recorded 1,597 deaths from brain cancer (956 men and 641 women). By 2025, this number is expected to rise slightly to 1,639 deaths (979 men and 660 women). The estimated risk of dying from brain cancer by age 85 in 2025 is 1 in 195 (0.51%), with the risk higher for males at 1 in 165 (0.61%) and lower for females at 1 in 240 (0.42%). Therefore, the rising incidence of brain tumors is driving the growth of the low-grade glioma industry.

Key Players In The Global Low-Grade Glioma Market

Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

Global Low-Grade Glioma Market Trends and Insights

Major companies operating in the low-grade glioma market are focusing on the integration of combination therapies and targeted therapy, such as genetic alteration drugs, to gain a competitive edge and enhance the treatment of children with low-grade glioma. Genetic alteration drugs are targeted therapies designed to modify or inhibit specific genetic mutations or abnormalities in cells, helping to treat diseases such as cancer by blocking the pathways that drive uncontrolled cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after receiving accelerated FDA approval. This targeted therapy is designed for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) with BRAF gene alterations. Offering a convenient once-weekly oral treatment, it addresses a crucial need for pediatric LGG patients with limited prior treatment options.

What Are Latest Mergers And Acquisitions In The Low-Grade Glioma Market?

In July 2024, Ipsen Biopharmaceuticals Inc., a US-based pharmaceutical company, collaborated with Day One Biopharmaceuticals Inc. to commercialize tovorafenib for pediatric low-grade glioma (pLGG) with BRAF mutations. This collaboration aims to expand global access to the treatment while leveraging Ipsen’s oncology expertise and international reach to accelerate regulatory and commercial efforts outside the US. Day One Biopharmaceuticals is a US-based clinical-stage biopharmaceutical company that is primarily focused on developing targeted therapies for pediatric low-grade glioma.

Regional Outlook

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Low-Grade Glioma Market?

The low-grade glioma market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, and targeted therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The low-grade glioma market also includes sales of astrocytomas, oligodendrogliomas, and ependymomas. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Low-Grade Glioma Market Report 2026?

The low-grade glioma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the low-grade glioma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.